Tailoring access to high cost, genetically targeted drugs

Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.

Saved in:
Bibliographic Details
Published in:Medical journal of Australia 2005-06, Vol.182 (12), p.607-608
Main Authors: Hall, Wayne D, Ward, Robyn, Liauw, Winston S, Brien, Jo‐anne E, Lu, Christine Y
Format: Article
Language:English
Subjects:
Advisory Committees
Australia
Collaboration
Confidentiality
Cost-Benefit Analysis
Decision Making, Organizational
Drug Approval
Drug Costs
Drugs
Expenditures
Financing, Government
Health Services Accessibility - economics
Hospitals
Humans
Insurance, Pharmaceutical Services - economics
Patients
Pharmaceutical industry
Pharmaceutical preparations
Pharmacogenetics
Privacy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.
ISSN:0025-729X
1326-5377
DOI:10.5694/j.1326-5377.2005.tb06844.x